ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to Progression in Phase 2 Trial in Second-Line Hepatocellular Carcinoma
Press Release issued by ArQule on January 17, 2012.
CE3 Inc. contributed to the conduct and execution of this study.
- Select the following link to view the article:
- http://investors.arqule.com/releasedetail.cfm?ReleaseID=639538
FIRST IN HUMAN STUDY WITH ARQ 621, A NOVEL INHIBITOR OF Eg5: FINAL RESULTS
Presented at the 2011 Annual Meeting of ASCO • Chicago, IL • 3-7 June 2011
CE3 Inc. contributed to the conduct and execution of this study.
- Select the following link to view the article: 
- http://files.shareholder.com/downloads/ARQL/1323388424x0x475973/a6e22dc7-b015-4f8c-bbef-7951116bd074/ARQ621_ASCO2011-FinalDraft.pdf

Phase 1b Results of c-MET Inhibitor Tivantinib (ARQ 197) in Combination With Gemcitabine in a Cohort of Patients with Advanced Breast, Ovarian, or Uterine Tumors
Presented at: 2011 ASCO Annual Meeting; June 3-7, 2011; Chicago, Illinois.
CE3 Inc. contributed to the conduct and execution of this study
- Select the following link to view the article:
- http://files.shareholder.com/downloads/ARQL/1323388424x0x475363/988c46c5-29af-4290-9e90-863561bdbbbd/Gem%20combo%20ASCO%202011.pdf